January 2020

In this study, different technologies are described for ccfDNA purification, quantification, and characterization in a multicenter setting. The study was conducted within the framework of the Innovative Medicines Initiative (IMI) program CANCER-ID (http://www.cancer-id.eu) to establish standardized (pre-)analytical workflows for ccfDNA analysis. 

Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows

Rita Lampignano, Martin H.D. Neumann, Sabrina Weber, Vera Kloten, Andrei Herdean, Thorsten Voss, Daniel Groelz, Anna Babayan, Marco Tibbesma, Martin Schlumpberger, Francesca Chemi, Dominic G. Rothwell, Harriet Wikman, Jean-Pierre Galizzi, Inger Riise Bergheim, Hege Russnes, Benedetta Mussolin, Serena Bonin, Christine Voigt, Hanny Musa, Pamela Pinzani, Evi Lianidou, Ged Brady, Michael R. Speicher, Klaus Pantel, Fay Betsou, Ed Schuuring, Mikael Kubista, Wim Ammerlaan, Markus Sprenger-Haussels, Thomas Schlange, and Ellen Heitzer for the Innovative Medicines Initiative CANCER-ID Consortium

Clinical Chemistry, Volume 66, Issue 1, January 2020, Pages 149–160, https://doi.org/10.1373/clinchem.2019.306837